Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors)

BACKGROUND: Cases of coronavirus disease 2019 (COVID-19) requiring hospitalization continue to appear in vulnerable populations, highlighting the importance of novel treatments. The hyperinflammatory response underlies the severity of the disease, and targeting this pathway may be useful. Herein, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonifácio, Lívia Pimenta, Ramacciotti, Eduardo, Agati, Leandro Barile, Vilar, Fernando Crivelenti, da Silva, Anna Christina Tojal, Louzada, Paulo, da Fonseca, Benedito Antônio Lopes, de Souza, Hayala Cristina Cavenague, de Oliveira, Caroline Candida Carvalho, Aguiar, Valéria Cristina Resende, Quadros, Carlos Augusto de Aguiar, Dusilek, Cesar, Itinose, Kengi, Risson, Ricardo, Ferreira, Lucas Roberto Rivabem, Lopes, Renato Delascio, Kallas, Esper Georges, Bellissimo-Rodrigues, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Medicina Tropical - SBMT 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10109354/
https://www.ncbi.nlm.nih.gov/pubmed/37075454
http://dx.doi.org/10.1590/0037-8682-0565-2022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10109354/
https://www.ncbi.nlm.nih.gov/pubmed/37075454
http://dx.doi.org/10.1590/0037-8682-0565-2022

Ejemplares similares